
Gallus BioPharmaceutical Aquires CMO Laureate Biopharmaceutical Services
he CMO Gallus BioPharmaceutical has acquired the biologics CMO Laureate Biopharmaceutical Services.
Gallus has clinical and commercial suites at both sites, with 50-L to 2000-L GMP single-use platforms from Xcellerex and HyClone in addition to 50-L to 2000L fixed and flexible stainless-steel bioreactors and associated downstream purification for drug substances.
Source:
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





